Peer-reviewed veterinary case report
Stem-cell treatment tested for heart disease in Dobermanns
By Pogue, B et al.·Published in The Journal of small animal practice·2013·Department of Small Animal Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Stem-cell therapy for dilated cardiomyopathy: a pilot study evaluating retrograde coronary venous delivery.
- Species:
- dog
Plain-English summary
A group of Doberman dogs with dilated cardiomyopathy (a heart condition) received stem-cell therapy through a special delivery method to see if it could help their heart function. While the treatment was safe for most dogs, one dog unfortunately died from a heart issue shortly after the procedure. The remaining dogs were monitored for up to two years, but their heart condition continued to worsen, and the average survival time after treatment was about 620 days. Overall, this study suggests that while the stem-cell therapy was safe, it did not significantly improve survival compared to other treatments for this condition.
People also search for: Doberman dilated cardiomyopathy treatment · stem cell therapy for dog heart disease · dog heart problems survival rate
Abstract
OBJECTIVE: To evaluate retrograde coronary venous stem-cell delivery for Dobermanns with dilated cardiomyopathy. METHODS: Retrograde coronary venous delivery of adipose-derived mesenchymal stem cells transduced with tyrosine mutant adeno-associated virus 2 to express stromal-derived factor-1 was performed in Dobermanns with dilated cardiomyopathy. Cases were followed for 2 years and electrocardiograms (ECG), echocardiograms and Holter monitoring were performed. RESULTS: Delivery of cells was feasible in 15 of 15 dogs. One dog died following the development of ventricular fibrillation 24 hours after cell delivery. The remaining 14 dogs were discharged the following day without complications. Echocardiographic measurements of left ventricular size and function showed continued progression of disease. On the basis of Kaplan-Meier product limit estimates, median survival for dogs following stem-cell delivery was 620 days (range of 1-799 days). When including only the occult-dilated cardiomyopathy population and excluding those dogs already in congestive heart failure, median survival was 652 days (range of 46-799 days). CLINICAL SIGNIFICANCE: Retrograde venous delivery of tyrosine mutant adeno-associated virus 2-stromal-derived factor-1 adipose-derived mesenchymal stem cells appears safe. Stem-cell therapy in dogs with occult-dilated cardiomyopathy does not appear to offer advantage compared to recently published survival data in similarly affected Dobermanns.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/23731226/